Group 1 - Vanda Pharmaceuticals Inc. will participate in the ASCP Annual Meeting from May 27 to May 30, 2025, presenting pharmacokinetic results of Milsaperidone and Iloperidone [1] - The presentation will include a poster titled "Pharmacokinetic Results of Single-Dose and Multiple-Dose Bioequivalence Studies of Milsaperidone and Iloperidone Immediate-Release Oral Tablets" [1] Group 2 - Bysanti™ is a new atypical antipsychotic drug that, if approved, could be available for sale in the US in 2026 [2] - Bysanti™ is expected to interact with various neurotransmitter receptors, including alpha-adrenergic, serotonin, and dopamine receptors [2] - Patent exclusivity for Bysanti™ could extend into the 2040s [2] Group 3 - Vanda Pharmaceuticals Inc. is focused on developing and commercializing innovative therapies to meet high unmet medical needs [3]

In my view, there has never been a better time to be a careful stock-picker. Investors are visibly getting nervous as the stock market rebounds to year-to-date highs, despite the ongoing threat of tariffs and a softer macroeconomy. As such, I prefer smaller-capWith combined experience of covering technology companies on Wall Street and working in Silicon Valley, and serving as an outside adviser to several seed-round startups, Gary Alexander has exposure to many of the themes shaping the industry today. He ...

Company Overview - Building Benjamins is a free stock picking and market commentary investment newsletter published by Tradition Investment Management, LLC, a registered investment adviser [1] - The founder, Benjamin Halliburton, has a notable background in investment management, having founded Tradition Capital Management in 2000 and received multiple accolades for his performance [1] Founder Background - Benjamin Halliburton began his investment career at Merrill Lynch in 1986 and has been continuously involved in investing since then [1] - He earned an MBA with a focus on finance from Duke's Fuqua School of Business in 1990 and was recognized as a Fuqua Scholar [1] - Halliburton holds the Chartered Financial Analyst designation and was the top-performing portfolio manager at Brundage, Story and Rose, where his strategy outperformed the S&P 500 during the 1990s bull market [1] Performance Recognition - Halliburton was named "PSN Manager of the Decade" for All-Cap in the 2000s and for Dividend Value in the 2010s, highlighting his successful investment strategies [1] - He was recognized as the youngest partner at his firm and received high praise from senior managing partners for his investment acumen [1]

Châtillon, France, May 15, 2025 Combined General Meeting of June 11, 2025 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), will hold its Combined General Meeting (the “General Meeting”) on June 11, 2025, at 02:00 p.m. CEST (08:00 a.m EST) at the Company’s headquarters located at IRO Building, 107 Avenue de la République, ...

Châtillon, France, May 15, 2025 Combined General Meeting of June 11, 2025 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), will hold its Combined General Meeting (the “General Meeting”) on June 11, 2025, at 02:00 p.m. CEST (08:00 a.m EST) at the Company’s headquarters located at IRO Building, 107 Avenue de la République, ...

Company Overview - indie Semiconductor, Inc. (NASDAQ: INDI) is a U.S. semiconductor company primarily focused on the automotive sector and also offers software solutions [1] Current Performance - The company has experienced poor performance amid ongoing geopolitical issues [1] - Recent easing of tensions may provide a potential for recovery [1] Investment Insights - The analyst expresses interest in initiating a long position in INDI within the next 72 hours [2]

Core Viewpoint - Investors often prefer stocks with a low price-to-earnings (P/E) ratio, believing that a lower P/E indicates higher stock value and potential for growth [1] Group 1: P/E Ratio Insights - Stocks with a rising P/E ratio can also yield strong returns, indicating that investors are willing to pay more for expected future earnings growth [2][3] - A rising P/E ratio suggests investor confidence in a company's fundamentals and anticipated positive performance [4] - Historical data shows that stocks can experience P/E ratio increases of over 100% from their breakout points, highlighting the potential for significant gains if stocks are selected early in their breakout cycle [5] Group 2: Stock Screening Criteria - The screening parameters for identifying stocks with increasing P/E include: - Current year EPS growth estimate should be greater than or equal to last year's actual growth [7] - Price changes over four weeks should exceed those over 12 weeks, and similarly for 12 weeks compared to 24 weeks, indicating consistent price increases [7][8] - Price change for 12 weeks should be at least 20% higher than for 24 weeks, but not exceed 100%, suggesting an impending uptrend [8] Group 3: Selected Stocks - The screening process narrowed down over 7,700 stocks to 83, with notable mentions including: - Comfort Systems USA (Zacks Rank 1) with an average four-quarter earnings surprise of 17.57% [9][10] - MasTec (Zacks Rank 2) with an average four-quarter earnings surprise of 26.03% [10] - Virgin Galactic (Zacks Rank 2) with an average four-quarter earnings surprise of 21.99% [11] - AeroVironment (Zacks Rank 2) with an average four-quarter earnings surprise of 18.40% [11] - Blackbaud (Zacks Rank 1) with an average four-quarter earnings surprise of 1.20% [12]

Corvus Pharmaceuticals (CRVS) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good afternoon, everyone. Thank you for standing by, and welcome to the Carvus Pharmaceuticals first quarter twenty twenty five business update and financial results conference call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session, and instructions will follow at that time. It is now my pleasure to turn the call over to Zach Kubo of Real Chemistry. Please go ah ...

Summary of Astria Therapeutics Conference Call Company Overview - **Company**: Astria Therapeutics (ATXS) - **Focus**: Development of first-choice products for allergic and immunologic diseases, particularly hereditary angioedema (HAE) [5][6] Key Products and Pipeline - **Lead Program**: Nivenabart - **Type**: Monoclonal antibody inhibitor of plasma calacrine - **Efficacy**: Demonstrated over 90% attack rate reduction in phase 1b/2 trial with dosing options of every three months or six months [6][12][17] - **Market Potential**: Expected market size for HAE to reach approximately $5.4 billion by 2030, driven by earlier diagnosis, increased use of preventative therapies, and geographic expansion [12] - **Competitive Advantage**: Aims to be a first-choice option due to its favorable dosing schedule and efficacy profile compared to existing treatments like TEXYRO, which requires bi-weekly dosing [19][13] - **Second Program**: STAR310 - **Type**: Monoclonal antibody antagonist of the OX40 receptor - **Current Status**: In phase 1a trial with initial results expected in Q3 [8][59] - **Mechanism**: Designed to avoid safety issues seen in previous OX40 programs, aiming for a differentiated profile in treating atopic dermatitis [61][62] Market Landscape and Competitive Analysis - **HAE Market**: Competitive with several existing therapies, but Nivenabart's unique dosing schedule and efficacy could position it as a market leader [9][14] - **Patient Willingness to Switch**: Evidence suggests patients are open to switching to new therapies that offer better efficacy and tolerability [15][16] - **Regulatory Strategy**: Phase 3 trial designed to test both dosing regimens (every three and six months) globally, with a focus on patient experience [30][66] Clinical Trial Insights - **Phase 1b/2 Trial Results**: Showed significant reductions in attack rates and severity of attacks, with a favorable safety profile [17][28] - **Phase 3 Trial Design**: Single trial to support both dosing regimens, with a primary endpoint of attack rate reduction at six months [29][30] - **Long-term Data**: Upcoming data from the Alpha Solar trial expected to provide insights into long-term safety and efficacy [24][67] Financial Position and Future Milestones - **Cash Position**: Strong cash reserves expected to last until mid-2027, covering key milestones for Nivenabart [66] - **Upcoming Milestones**: - Mid-year: Alpha Solar long-term extension data for Nivenabart - Q3: Phase 1a data for STAR310 [67] Conclusion - Astria Therapeutics is positioned to make significant strides in the treatment of hereditary angioedema and atopic dermatitis with its innovative therapies, Nivenabart and STAR310. The company is focused on delivering compelling clinical data and navigating a competitive landscape to establish itself as a leader in these therapeutic areas.

Core Insights - MojiWeather launched the Global Tropical Cyclone feature on April 24, 2025, utilizing multi-model fusion and AI algorithms for accurate predictions of tropical cyclone intensity, landfall locations, and impact zones [1][3][9] Industry Context - The destructive power of tropical cyclones is increasing due to climate change, with 2024 natural disasters causing $320 billion in global losses, of which tropical cyclones accounted for $133 billion or 41% [2] - Over the past decade, climate change has raised the average intensity of tropical cyclones by 67%, and if global temperatures rise by 2°C, related economic losses could double [2] Company Developments - The Global Tropical Cyclone feature provides real-time updates on critical parameters such as location, wind speed, movement direction, and intensity, enabling users to adjust travel plans and emergency responses [4][5] - The feature supports multiple languages including English, French, Spanish, and Portuguese, catering to global users in tropical cyclone-prone regions [7] - MojiWeather employs dynamic path animations and combines them with 48-hour precipitation maps and wind field overlays for enhanced data visualization [8] - The launch of this feature expands MojiWeather's capabilities in weather services, aiming to improve forecast precision and broaden service offerings [9]